Stem cell transplantation for thalassaemia.
Although improvements in conventional treatment have enhanced the prognosis of thalassaemia, stem cell transplantation remains the only cure. Over the last 2 decades, progress in preventive strategies, effective control of transplant related complications and development of new preparative regimens, have considerably improved the results of transplants from HLA-identical siblings. Currently class 1, class 2 and class 3 patients receiving bone marrow transplantation (BMT) from an HLA-identical related donor have 87, 85 and 80% of probability of thalassaemia-free survival. The results of transplant in adult patients treated with current protocols are less successful. This study reports experience with BMT for thalassaemia.
Gaziev
Javid
J
Mediterranean Institute of Hematology, International Centre for Transplantation in Thalassemia and Sickle Cell Anemia, Azienda Ospedaliera San Camillo, Forlanini di Roma, Italy. j.gaziev@fondazioneime.org
Lucarelli
Guido
G
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D046528:Chimerism; D006086:Graft vs Host Disease; D006801:Humans; D007223:Infant; D019190:Iron Overload / Q000628:therapy; D033581:Stem Cell Transplantation; D017086:beta-Thalassemia / Q000628:therapy*